SCHEMBL3521940

SCHEMBL3521940

O=C(O)c1c(O)c(Br)cc2nc(-c3nccs3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKMYT1 Q99640 1/20 0.35
RAB9A P51151 1/20 0.35
MCL1 Q07820 1/20 0.34
TACR3 P29371 1/20 0.34
ECE1 P42892 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMPD3 Q9NY59 1/20 0.32
HSP90AA1 P07900 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
FEN1 P39748 1/20 0.31
GSK3A P49840 2/20 0.31
GSK3B P49841 2/20 0.31
TTR P02766 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520838 0.86 HPGD (0.42) HPGDCYP3A4CYP2C9PKMYT1RAB9A
SCHEMBL3537880 0.85 EGLN3 (0.43) HPGDMCL1TACR3
SCHEMBL3519937 0.81 RXFP1 (0.47) HPGDRAB9AKDM4EMEN1KMT2A
SCHEMBL3532359 0.78 LMNA (0.37) HPGDCYP3A4CYP2C9PKMYT1TACR3
SCHEMBL3521139 0.78 TSHR (0.38) HPGDCYP3A4CYP2C9PKMYT1RAB9A
SCHEMBL3526186 0.77 KMO (0.40) HPGDMCL1KDM4EGSK3AGSK3B
SCHEMBL3523288 0.74 KMO (0.44) CYP2C9DHODH
SCHEMBL3519604 0.72 KDM4E (0.45) KDM4EHSP90AA1MEN1KMT2ATTR
SCHEMBL3530230 0.72 EGLN3 (0.50) HPGDCYP3A4CYP2C9PKMYT1MCL1
SCHEMBL3518822 0.69 HPGD (0.38) HPGDCYP3A4CYP2C9PKMYT1TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 HPGD 51/4885CYP3A4 824/4885CYP2C9 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.